Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.54 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | QPCT | Q16769 | 1/20 | 0.46 |
| ▸ | QPCTL | Q9NXS2 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16185925 | 0.92 | SLC15A2 (0.54) | SLC15A2GHSRNLN | |
| SCHEMBL16187205 | 0.84 | NLN (0.47) | SLC15A2NLN | |
| SCHEMBL27706632 | 0.83 | SLC15A2 (0.74) | SLC15A2GHSR | |
| SCHEMBL30911281 | 0.83 | SLC15A2 (0.74) | SLC15A2GHSR | |
| SCHEMBL27687339 | 0.81 | SLC15A2 (0.63) | SLC15A2GHSR | |
| SCHEMBL29774683 | 0.78 | SLC15A2 (0.72) | SLC15A2GHSR | |
| SCHEMBL29014876 | 0.78 | SLC15A2 (0.63) | SLC15A2GHSR | |
| SCHEMBL29774690 | 0.78 | SLC15A2 (0.72) | SLC15A2GHSR | |
| SCHEMBL30409074 | 0.77 | SLC15A2 (0.71) | SLC15A2GHSR | |
| SCHEMBL28027302 | 0.77 | SLC15A2 (0.71) | SLC15A2GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359282-B2 | Functionalized nanodiamonds as delivery platforms for nucleic acids | UNIVERSITY OF SASKATCHEWAN (CA) | 2016-06-07 | — | — | US | disclosed |
| US-9012838-B2 | Covalently functionalized nanodiamond-based MALDI matrices and methods of use thereof | UNIVERSITY OF SASKATCHEWAN (CA) | 2015-04-21 | — | — | US | disclosed |
| US-20140312218-A1 | COVALENTLY FUNCTIONALIZED NANODIAMOND-BASED MALDI MATRICES AND METHODS OF USE THEREOF | UNIVERSITY OF SASKATCHEWAN (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20140314850-A1 | FUNCTIONALIZED NANODIAMONDS AS DELIVERY PLATFORMS FOR NUCLEIC ACIDS | UNIVERSITY OF SASKATCHEWAN (CA) | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140312218-A1 | COVALENTLY FUNCTIONALIZED NANODIAMOND-BASED MALDI MATRICES AND METHODS OF USE THEREOF | ITGA2B, MMP2, ITGAV | SLC15A2 3731/4885GHSR 4785/4885NLN 145/4885 |
| US-20140314850-A1 | FUNCTIONALIZED NANODIAMONDS AS DELIVERY PLATFORMS FOR NUCLEIC ACIDS | ANXA7, ANXA6, NSUN2 | SLC15A2 1509/4885GHSR 4731/4885NLN 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.